Introduction: Anaplastic lymphoma kinase (ALK) gene rearrangement characterizes a subgroup of patients with lung adenocarcinoma who may benefit from ALK inhibitors. Fluorescence in situ hybridization (FISH) with a break-apart/split-signal strategy is the gold standard to investigate ALK. The cutoff to define ALK positivity has been settled at 15% or greater. A subset of patients has ALK borderline status, showing 15% +/- 5% positive cells. Several aspects, both biological and technical, might influence signals evaluation, making FISH interpretation a challenging task. To improve ALK evaluation, we classified the different FISH patterns on the basis of the type of the split signals, namely short, long, far away, and deleted.Methods: We inves...
International audienceAnaplastic lymphoma kinase (ALK) gene rearrangements in lung adenocarcinoma re...
INTRODUCTION Detection of anaplastic lymphoma kinase (ALK)-gene rearrangements in non-small-cell lu...
Introduction:Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7% of non–small-cell lun...
Introduction: Anaplastic lymphoma kinase (ALK) gene rearrangement characterizes a subgroup of patien...
IntroductionAnaplastic lymphoma kinase (ALK) gene rearrangement characterizes a subgroup of patients...
Objectives: Targeted therapies in the management of patients with lung cancer provide significantly ...
IntroductionALK gene rearrangements occur in approximately 5% of lung adenocarcinomas (ACAs), leadin...
BACKGROUND: Anaplastic lymphoma kinase (ALK) rearrangement represents a landmark in the targeted the...
Introduction:Accurate, cost-effective methods for testing anaplastic lymphoma kinase gene rearrangem...
IntroductionBreak-apart fluorescence in situ hybridization (FISH) is the FDA-approved assay for dete...
IntroductionPatients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (A...
INTRODUCTION ALK gene rearrangements occur in ~5% of lung adenocarcinomas (ACA), leading to ALK ove...
Aims: Accurate assessment of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small-cell l...
Abstract Background Rearrangements of the anaplastic lymphoma kinase (ALK) belong to the promising t...
Abstract Background Anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangements have been...
International audienceAnaplastic lymphoma kinase (ALK) gene rearrangements in lung adenocarcinoma re...
INTRODUCTION Detection of anaplastic lymphoma kinase (ALK)-gene rearrangements in non-small-cell lu...
Introduction:Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7% of non–small-cell lun...
Introduction: Anaplastic lymphoma kinase (ALK) gene rearrangement characterizes a subgroup of patien...
IntroductionAnaplastic lymphoma kinase (ALK) gene rearrangement characterizes a subgroup of patients...
Objectives: Targeted therapies in the management of patients with lung cancer provide significantly ...
IntroductionALK gene rearrangements occur in approximately 5% of lung adenocarcinomas (ACAs), leadin...
BACKGROUND: Anaplastic lymphoma kinase (ALK) rearrangement represents a landmark in the targeted the...
Introduction:Accurate, cost-effective methods for testing anaplastic lymphoma kinase gene rearrangem...
IntroductionBreak-apart fluorescence in situ hybridization (FISH) is the FDA-approved assay for dete...
IntroductionPatients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (A...
INTRODUCTION ALK gene rearrangements occur in ~5% of lung adenocarcinomas (ACA), leading to ALK ove...
Aims: Accurate assessment of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small-cell l...
Abstract Background Rearrangements of the anaplastic lymphoma kinase (ALK) belong to the promising t...
Abstract Background Anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangements have been...
International audienceAnaplastic lymphoma kinase (ALK) gene rearrangements in lung adenocarcinoma re...
INTRODUCTION Detection of anaplastic lymphoma kinase (ALK)-gene rearrangements in non-small-cell lu...
Introduction:Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7% of non–small-cell lun...